机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital andGuangdong Academy of Medical Sciences, Southern Medical University, Guangzhou,China广东省人民医院[2]Respiratory medicine, The First Affiliated Hospital, Zhejiang University SchoolOf Medicine, Hangzhou, China浙江大学医学院附属第一医院[3]Oncology, Jilin Cancer Hospital, Changchun, China[4]Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou,China[5]Thoracic Oncology, Shulan Hospital, Hangzhou, China[6]Oncology, The FirstAffiliated Hospital of Henan University of Science and Technology, Luoyang, China[7]Oncology, North Hospital, Affiliated Hospital of Hebei University, Baoding, China河北大学附属医院[8]Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[9]R&D, WanbangBiopharmaceuticals, Jiangsu, China[10]Translational Medicine, Beijing Fosun Pharmaceutical Research and Development Co., Ltd., Shanghai, China[11]Clinical Oncology,Beijing Fosun Pharmaceutical Research and Development Co., Ltd., Beijing, China[12]Biometrics and Data Science, Beijing Fosun Pharmaceutical Technology Development Co., Ltd., Beijing, China[13]Global R&D Center, Shanghai Fosun PharmaceuticalDevelopment Co., Ltd, Shanghai, China
第一作者机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital andGuangdong Academy of Medical Sciences, Southern Medical University, Guangzhou,China
推荐引用方式(GB/T 7714)：
J-J. Yang,J. Zhou,Y. Cheng,et al.ctDNA analysis of SAF-189s efficacy in ALK plus advanced nonsmall cell lung cancer (NSCLC)[J].ANNALS OF ONCOLOGY.2023,34:doi:10.1016/j.annonc.2023.09.2397.
APA：
J-J. Yang,J. Zhou,Y. Cheng,M. Li,Q. Zhao...&Y-L. Wu.(2023).ctDNA analysis of SAF-189s efficacy in ALK plus advanced nonsmall cell lung cancer (NSCLC).ANNALS OF ONCOLOGY,34,
MLA：
J-J. Yang,et al."ctDNA analysis of SAF-189s efficacy in ALK plus advanced nonsmall cell lung cancer (NSCLC)".ANNALS OF ONCOLOGY 34.(2023)
医学